igm biosciences news - Search News

IGM Biosciences to cut 73% of workforce

Hosted on MSN · 3d

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

YAHOO!Finance · 2d

IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Seeking Alpha on MSN · 3d

IGM to slash 73% of workforce, halt two drug programs

IGM Biosciences (IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates in the wake of disappointing drug data. Read more here.

MarketWatch · 2d

IGM Biosciences Shares Down 69% Following Treatment Development Halt, Workforce Reduction

IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments. Shares were trading around $1.94. The stock is up 1.5% on the year.

Business Insider · 1d

IGM Biosciences Halts Antibody Therapies, Cuts Workforce

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your

12h

IGM Biosciences (NASDAQ:IGMS) Given New $2.00 Price Target at Truist Financial

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

1d

IGM Biosciences Stock: Bad News With No Turnaround In Sight

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

13h

IGM Biosciences (NASDAQ:IGMS) Given “Hold” Rating at Jefferies Financial Group

IGM Biosciences (NASDAQ:IGMS – Get Free Report)‘s stock had its “hold” rating reiterated by equities researchers at Jefferies ...

Hosted on MSN1d

Stifel Downgrades IGM Biosciences (IGMS)

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

2d

IGM Biosciences price target lowered to $2 from $12 at Truist

Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...

1d

IGM Biosciences downgraded to Hold from Buy at Jefferies

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results